Identifying biomarkers that reflect changes in copper metabolism, such as copper content in plasma and serum, ceruloplasmin (Cp), and copper complex (SOD), can detect atherosclerosis risk early before clinical symptoms appear. The gene discussed is CP; the disease is atherosclerosis.